Bone marrow microvessel density and plasma angiogenic factors in myeloproliferative neoplasms: clinicopathological and molecular correlations

Increased angiogenesis in BCR-ABL1 negative myeloproliferative neoplasms (MPNs) has been recognized, but its connection with clinical and molecular markers needs to be defined. The aims of study were to (1) assess bone marrow (BM) angiogenesis measured by microvessel density (MVD) using CD34 and CD1...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2017-03, Vol.96 (3), p.393-404
Main Authors: Lekovic, Danijela, Gotic, Mirjana, Skoda, Radek, Beleslin-Cokic, Bojana, Milic, Natasa, Mitrovic-Ajtic, Olivera, Nienhold, Ronny, Sefer, Dijana, Suboticki, Tijana, Buac, Marijana, Markovic, Dragana, Diklic, Milos, Cokic, Vladan P.
Format: Article
Language:English
Subjects:
Adult
Aged
Angiogenesis Inducing Agents - blood
Bone Marrow - blood supply
Bone Marrow - metabolism
Bone Marrow - pathology
Female
Hematology
Humans
Male
Medicine
Medicine & Public Health
Microvessels - metabolism
Microvessels - pathology
Middle Aged
Myeloproliferative Disorders - blood
Myeloproliferative Disorders - pathology
Neovascularization, Pathologic - blood
Neovascularization, Pathologic - pathology
Oncology
Original Article
Prospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Increased angiogenesis in BCR-ABL1 negative myeloproliferative neoplasms (MPNs) has been recognized, but its connection with clinical and molecular markers needs to be defined. The aims of study were to (1) assess bone marrow (BM) angiogenesis measured by microvessel density (MVD) using CD34 and CD105 antibodies; (2) analyze correlation of MVD with plasma angiogenic factors including vascular endothelial growth factor, basic fibroblast growth factor, and interleukin-8; (3) examine the association of MVD with clinicopathological and molecular markers. We examined 90 de novo MPN patients (30 polycythemia vera (PV), primary myelofibrosis (PMF), essential thrombocythemia (ET)) and 10 age-matched controls. MVD was analyzed by immunohistochemistry “hot spot” method, angiogenic factors by immunoassay and JAK2V617F , and CALR mutations by DNA sequencing and allelic PCR. MVD was significantly increased in MPNs compared to controls (PMF > PV > ET). Correlation between MVD and plasma angiogenic factors was found in MPNs. MVD was significantly increased in patients with JAK2 V617F mutation and correlated with JAK2 mutant allele burden (CD34-MVD: ρ = 0.491, p  
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-016-2890-9